AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Subscribe To Our Newsletter & Stay Updated